Transparence Statement
The lead author affirms that this manuscript is an honest, accurate, and
transparent account of the study being reported; that no important
aspects of the study have been omitted; and that any discrepancies from
the study as planned (and, if relevant, registered) have been explained.
Contributors: JL and PVB contributed equally to this article.
JL and PVB conceptualized the paper. JL analysed the data, with input
from CM, RF, RPV and VF. JL and CM wrote the initial draft with all
authors providing critical feedback and edits to subsequent revisions.
All authors approved the final draft of the manuscript. PVB is the
guarantor. The corresponding author attests that all listed authors meet
authorship criteria and that no others meeting the criteria have been
omitted.
Ethics approval: This study received the Ethics Committee of
Centro Hospitalar Universitário São João approval, nº182/19.
Funding : no funding
1. Pérez-Lópes F. Postmenopausal Diseases and Disorders. Postmenopausal
Diseases and Disorders. 2019.
2. Day T, Otton G, Jaaback K, Weigner J, Scurry J. Is Vulvovaginal
Lichen Planus Associated with Squamous Cell Carcinoma? J Low Genit Tract
Dis. 2018;22(2):159–65.
3. Day T, Bowden N, Jaaback K, Otton G, Scurry J. Distinguishing erosive
lichen planus from differentiated vulvar intraepithelial neoplasia. J
Low Genit Tract Dis. 2016;20(2):174–9.
4. Regauer S, Eberz B, Reich O. Human Papillomavirus-Induced Squamous
Intraepithelial Lesions in Vulvar Lichen Planus. J Low Genit Tract Dis.
2016;20(4):360–4.
5. Preti M, Micheletti L, Privitera S, Radici G, Gallio N, Benedetto C
BL. Vulvar Lichen Planus: A Risk Factor for Vulvar High-Grade Squamous
Intraepithelial Lesion Recurrence?
6. Preti M, Rotondo JC, Holzinger D, Micheletti L, Gallio N,
McKay-Chopin S, et al. Role of human papillomavirus infection in the
etiology of vulvar cancer in Italian women. Infect Agent Cancer.
2020;15(1):4–11.
7. Halonen P, Jakobsson M, Heikinheimo O, Riska A, Gissler M, Pukkala E.
Cancer risk of Lichen planus: A cohort study of 13,100 women in Finland.
Int J Cancer. 2018;142(1):18–22.
8. Regauer S, Reich O, Eberz B. Vulvar cancers in women with vulvar
lichen planus: A clinicopathological study. J Am Acad Dermatol.
2014;71(4):698–707.
9. Lynch PJ. 2006 International Society for the Study of Vulvovaginal
Disease classification of vulvar dermatoses: a synopsis. Vol. 11,
Journal of lower genital tract disease. United States; 2007. p. 1–2.
10. Lynch PJ, Moyal-barrocco M, Bogliatto F, Micheletti L, Scurry J.
2006 ISSVD Classification of Vulvar Dermatoses. J Reprod Med. 2006;3–9.
11. Lynch PJ, Moyal-Barracco M, Scurry J, Stockdale C. 2011 ISSVD
terminology and classification of vulvar dermatological disorders: An
approach to clinical diagnosis. J Low Genit Tract Dis.
2012;16(4):339–44.
12. Simpson RC, Thomas KS, Leighton P, Murphy R. Diagnostic criteria for
erosive lichen planus affecting the vulva: An international
electronic-Delphi consensus exercise. Br J Dermatol.
2013;169(2):337–43.
13. Micheletti L Bogliatto F, Zanotto-Valentino MC, Ghiringhello B,
Massobrio M PM. Vulval lichen planus in the practice of a vulval clinic.
Br J Dermatol 2000;143(6)1349–50. 2000;
14. Day T, Wilkinson E, Rowan D, Scurry J. Clinicopathologic Diagnostic
Criteria for Vulvar Lichen Planus. J Low Genit Tract Dis. 2020;00(00):1.
15. Simpson RC, Littlewood SM, Cooper SM, Cruickshank ME, Green CM,
Derrick E, et al. Real-life experience of managing vulval erosive lichen
planus: A case-based review and U.K. multicentre case note audit. Br J
Dermatol. 2012;167(1):85–91.
16. Mb CMRF, Torgerson RR, Davis MDP. patients at Mayo Clinic. J Am
Dermatology [Internet]. 2017;77(6):1053–9. Available from:
https://doi.org/10.1016/j.jaad.2017.07.030
17. Santegoets LAM, Helmerhorst TJM, Van Der Meijden WI. A retrospective
study of 95 women with a clinical diagnosis of genital lichen planus. J
Low Genit Tract Dis. 2010;14(4):323–8.
18. Bilenchi R, Poggiali S, De Padova LA, Pisani C, De Paola M, Fimiani
M. Human papillomavirus reactivation following topical tacrolimus
therapy of anogenital lichen sclerosus [21]. Br J Dermatol.
2007;156(2):405–6.
19. Edey K, Bisson D, Kennedy C. Topical tacrolimus in the management of
lichen sclerosus [4]. BJOG An Int J Obstet Gynaecol.
2006;113(12):1482.
20. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of
cancer: How much cause for concern? Br J Dermatol. 2005;153(4):701–5.
21. Chin S, Scurry J, Bradford J, Lee G, Fischer G. Association of
Topical CorticosteroidsWith Reduced Vulvar Squamous Cell Carcinoma
Recurrence in PatientsWith Vulvar Lichen Sclerosus. JAMA Dermatol.
22. Howard M, Hall A. Vulval lichen planus–lichen sclerosus overlap.
Int J STD AIDS. 2018;29(10):1017–23.
23. ACOG. Clinical Management Guidelines for Obstetrician –
Gynecologists. Obstet Gynecol. 2019;133(76):168–86.
24. van der Meijden WI, Boffa MJ, ter Harmsel WA, Kirtschig G, Lewis FM,
Moyal-Barracco M, et al. 2016 European guideline for the management of
vulval conditions. J Eur Acad Dermatology Venereol. 2017;31(6):925–41.
25. Edwards SK, Bates CM, Lewis F, Sethi G, Grover D. 2014 UK national
guideline on the management of vulval conditions. Int J STD AIDS.
2015;26(9):611–24.